

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER BKR-107 U.S. APPLICATION NO. 10/595859 (if known, see 37 CFR 1.5)
INTERNATIONAL APPLICATION NO. PCT/FR2005/000771	INTERNATIONAL FILING DATE March 30, 2005	PRIORITY DATE CLAIMED March 31, 2004; December 16, 2004
TITLE OF INVENTION Glycopeptides Derived from Pancreatic Structures, Antibodies and Applications Thereof in Diagnostics and Therapeutics		
APPLICANT(S) FOR DO/EO/US Dominique Lombardo, Eric Mas, Marie-Odile Sadoulet, Laurence Panicot-Dubois, Jean-Paul Bernard		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <u>signed</u> 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A preliminary amendment. 14. <input checked="" type="checkbox"/> An Application Data Sheet under 37 CFR 1.76. 15. <input type="checkbox"/> A substitute specification. 16. <input checked="" type="checkbox"/> A power of attorney and/or change of address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. 18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).		

IAP16 Rec'd PCT/PTO 22 SEP 2006

IAP16 Rec'd PCT/PTO 22 SEP 2006

PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER	
10/593859		PCT/FR2005/000771		BKR-107	
20. Other items or information: Copy of front page of the published PCT application					
The following fees have been submitted				CALCULATIONS	PTO USE ONLY
21.	<input checked="" type="checkbox"/>	Basic national fee (37 CFR 1.492(a))	\$300	\$ 300.00	
22.	<input checked="" type="checkbox"/>	Examination fee (37 CFR 1.492(c))		\$ 200.00	
If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4) ... \$0					
All other situations ... \$200					
23.	<input checked="" type="checkbox"/>	Search fee (37 CFR 1.492(b))		\$400.00	
If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4) ... \$0					
Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority ... \$100					
International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB ... \$400					
All other situations ... \$500					
TOTAL OF 21, 22 and 23 =				\$900.00	
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		
84 - 100 =	0 /50 =	0	x \$250	\$0.00	
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	22 - 20 =	2	x \$ 50	\$100.00	
Independent claims	6 - 3 =	3	x \$200	\$600.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360	\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$1,600.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.				\$0.00	
SUBTOTAL =				\$1,600.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).				\$	
TOTAL NATIONAL FEE =				\$1,600.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	
TOTAL FEES ENCLOSED =				\$1,600.00	
				Amount to be refunded:	\$
				Amount to be charged	\$

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


- a. ☐ A check in the amount of \$ _____ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 19-0065 in the amount of \$ 1,600.00 to cover the above fees.
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0065. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.

SEND ALL CORRESPONDENCE TO:

CUSTOMER NUMBER
23557

September 22, 2006
Date



SIGNATURE

Frank C. Eisenschenk, Ph.D.

NAME

45,332

REGISTRATION NUMBER

10/593859

Patent Application
Docket No. BKR-107

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Dominique Lombardo, Eric Mas, Marie-Odile Sadoulet, Laurence
Panicot-Dubois, Jean-Paul Bernard

Docket No. : BKR-107

For : Glycopeptides Derived from Pancreatic Structures, Antibodies and
Applications Thereof in Diagnostics and Therapeutics

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

CERTIFICATE OF MAILING BY EXPRESS MAIL (37 CFR §1.10)

Express Mail No.:


EQ829900237US

Date of Deposit: September 22, 2006

I hereby certify that the attached Transmittal Letter to the United States Designated/Elected Office (DO/EO/US), with copies as required for authorization for use of Deposit Account No. 19-0065, Preliminary Amendment, Application Data Sheet, Submission of Sequence Listing Under 37 CFR §§1.821-1.825, sequence listing on paper and computer readable format, cover page of published international application, English language translation of international application with certification, executed Declaration for Inventorship Under 4.17 and unexecuted Power of Attorney are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and are addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313.

David M. Gilland

Name of person mailing paper



Signature

10/593859


CERTIFICATE

I, Martine NION,

of Cabinet Becker & Associés
25, rue Louis le Grand
F-75002 PARIS (France),

do hereby declare that I am conversant with the French and English Languages, and
that the attached translation signed by me is, to the best of my knowledge and belief,
a true and correct translation of International Patent Application
No. PCT/FR2005/000771 filed on March 30, 2005

Dated : August 29, 2006

Signed : 
Martine NION